Cyclarity develops interventions targeting toxic forms of cholesterol to provide true disease-modifying treatments for age-related diseases.
Cyclarity Therapeutics has raised $10.3M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in December 2024.
Cyclarity Therapeutics's investors include Formic Ventures, KIZOO Technology Capital, Michael Antonov, Harald McPike.
Cyclarity Therapeutics is headquartered in Novato, United States.
Cyclarity develops interventions targeting toxic forms of cholesterol to provide true disease-modifying treatments for age-related diseases.
Cyclarity Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cyclarity Therapeutics — Funding & Investors." VCBacked, December 30, 2024, https://www.vcbacked.co/company/cyclarity-therapeutics. Accessed August 15, 2026.
VCBacked. (2024). Cyclarity Therapeutics — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/cyclarity-therapeutics
{{cite web |title=Cyclarity Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/cyclarity-therapeutics |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated